๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia
NCT06955858Hematopoietic Stem Cell Mobilization
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
60
Tianjin
2025-05-30
Not yet open
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
NCT06993025Biliary Tract Cancer
DrugBevacizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-05-25
Recruiting
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
NCT06974929Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
80
Tianjin
2025-05-22
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06880354Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
37
Tianjin
2025-05-22
Recruiting
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
NCT06992128Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
129
Tianjin
2025-05-22
Recruiting
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD๏ผˆ Breakthrough Invasive Fungal Disease๏ผ‰ in Patients With Malignant Hematological Diseases
NCT07135778Invasive Fungal Disease
Institute of Hematology & Blood Diseases Hospital, China
Observational
36
Tianjin
2025-05-19
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Guangzhou, Hangzhou, Hengyang, Nanning, Shenzhen, Taiyuan, Tianjin, Zhengzhou
2025-05-19
Recruiting
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
NCT06970119Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 1/2
55
Wuxi, Tianjin
2025-05-14
Active, closed
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT06934044Multiple Myeloma
DrugsCevostamab·Tocilizumab
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
NCT06773507Advanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)
DrugBC008-1A
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Phase 1
80
Tianjin
2025-05-12
Recruiting
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
NCT06929299Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xiโ€™an, Tianjin
2025-05-12
Recruiting
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ยฑ ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132Relapsed or Refractory Aggressive B-cell Lymphoma
DrugsCar-T·Glofitamab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
25
Tianjin
2025-05-09
Recruiting
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NCT06917092Endometrial Adenocarcinoma, Endometrial Cancer
DrugIparomlimab and Tuvonralimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-05-01
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06978699PNH - Paroxysmal Nocturnal Hemoglobinuria
DrugXH-S003
S-INFINITY Pharmaceuticals Co., Ltd
Phase 2
24
Tianjin
2025-04-30
Recruiting
A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
NCT06915142Advanced Malignant Tumour
Shandong Suncadia Medicine Co., Ltd.
Phase 2
300
Beijing, Tianjin
2025-04-28
Not yet open
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
NCT06900088Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
DrugSelinexor
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-04-25
Recruiting
GR1803 Injection in Patients With RRMM
NCT06952075Multiple Myleoma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
30
Tianjin
2025-04-24
Recruiting
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
NCT06948981Hematological Malignancy (Leukemia- Lymphoma)
DrugGT719
Grit Biotechnology
Phase 1/2
46
Tianjin
2025-04-18
Recruiting
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
NCT07347171Leukemia, AML, MDS, AML (Acute Myelogenous Leukemia)
Cullgen (Shanghai),Inc
Phase 1
45
Nanchang, Tianjin, Wuhan
2025-04-17
Recruiting
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
NCT06743503Large B-cell Lymphoma
DrugRapamycin
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
70
Nanjing, Tianjin
2025-04-11
Recruiting
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
NCT07022197Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder, Myasthenia Gravis, Idiopathic Inflammatory Myopathies
Tianjin Medical University General Hospital
Phase 1/2
27
Tianjin
2025-04-10
Recruiting
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
NCT06793475Extramedullary Multiple Myeloma
DrugsThalidomide·Carfilzomib·Dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Beijing, Tianjin
2025-04-09
Recruiting
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
NCT07087223Non Small Cell Lung Cancer NSCLC
DrugsVebreltinib·Furmonertinib
Peking University Cancer Hospital & Institute
Phase 1/2
42
Neimeng, Baoding, Baotou, Beijing, Dalian, Tianjin
2025-04-08
Recruiting
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
NCT06958679B-cell Malignancies, Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
132
Tianjin
2025-04-03
Recruiting
Alpha-Synuclein PET/CT in Various ฮฑ-Syn-Related Disease
NCT06949670Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2025-04-01
Recruiting
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
NCT06939127NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
38
Tianjin
2025-04-01
Recruiting
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06914037Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
DrugCHT101
Tianjin Medical University Cancer Institute and Hospital
Phase 1
24
Tianjin
2025-03-31
Recruiting
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
NCT07244003T2DM (Type 2 Diabetes Mellitus)
DrugsGanagliflozin·Liraglutide·Metformin
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 4
430
Tianjin
2025-03-29
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
NCT07249073Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
9
Tianjin
2025-03-28
Recruiting
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
NCT06944106Pancreatic Cancer
DrugBevacizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-03-28
Recruiting
Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial
NCT06932328Acute Pharyngitis
Jianmin Pharmaceutical Group Co., LTD.
Phase 2
216
Harbin, Changsha, Changchun, Jinan, Luzhou, Tianjin, Wenzhou
2025-03-26
Recruiting
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
NCT07185503Mucormycosis in Hematologic Malignancies
DrugLiposomal Amphotericin B
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Dalian, Harbin, Shenyang, Tianjin
2025-03-25
By invitation
Cohort of Cord Blood Bank
NCT07249099Health Status, Childhood Diseases
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,000
Tianjin
2025-03-25
Recruiting
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT06830031Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes, Follicular Lymphoma Grade 3B, PMBL
Shanghai Exuma Biotechnology Ltd.
Phase 1
18
Tianjin
2025-03-25
Recruiting
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
NCT06792019Platelet Transfusion Refractoriness
DrugCM313
Keymed Biosciences Co.Ltd
Phase 1/2
110
Tianjin
2025-03-25
Recruiting
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
NCT06880393Multiple Myeloma
DrugAnti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2025-03-18
Recruiting
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
NCT06954558Advanced Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-03-18
Recruiting
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019Alzheimer Disease
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Recruiting
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
NCT06951997Metastatic Pancreatic Cancer
DrugsChidamide·Iparomlimab and Tuvonralimab·Nab-paclitaxel·Gemcitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2025-03-07
Recruiting
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT06880081Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
12
Guiyang, Nanchang, Jining, Tianjin, Kunming
2025-03-07
Recruiting
Clinical Study on the Safety and Efficacy of BCMA-CARTยฑASCT in Treating Young Multiple Myeloma Patients
NCT07169500Multiple Myeloma
DrugCar-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
NCT06838949Herombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2025-03-03
Recruiting
Reproductive and Mental Health of Patients With Aplastic Anemia
NCT06936930Aplastic Anemia, Reproductive Health
Institute of Hematology & Blood Diseases Hospital, China
Observational
600
Tianjin
2025-03-03
Recruiting
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
NCT07109323Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk, Primary Refractory, Early Progression
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
NCT06799611Immune Thrombocytopenia (ITP), Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-03-03
Recruiting
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
NCT06880419Acute Graft-versus-Host Disease
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
174
Tianjin
2025-03-03
Active, closed
Combination of Remimazolam and Propofol During Drug-induced Sleep Endoscopy
NCT06784479Sedative Effect During Drug-induced Sleep Endoscopy, Obstructive Sleep Apnea (OSA)
DrugPropofol
Dan Liu
Phase 4
174
Tianjin
2025-03-01
Recruiting
Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status
NCT07350928Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3
394
Tianjin
2025-03-01
Not yet open
Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
NCT06791824Aplastic Anemia
Keymed Biosciences Co.Ltd
Phase 1/2
125
Tianjin
2025-03
Recruiting
Second-line Immunotherapy for ES-SCLC
NCT06853678Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsSelinexor·Adebrelimab·Nab-paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Not applicable
30
Tianjin
2025-02-28
Recruiting
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
NCT06570447Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory
DrugsGlofitamab·Chidamide
Tianjin Medical University Cancer Institute and Hospital
Phase 2
22
Tianjin
2025-02-27
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
DrugTarlatamab
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
NCT06921980CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being
Institute of Hematology & Blood Diseases Hospital, China
Observational
20
Tianjin
2025-02-25
Recruiting
Nomogram for Astigmatism Correction of KLEx
NCT07605221Astigmatism
Tianjin Eye Hospital
Not applicable
100
Tianjin
2025-02-18
Recruiting
Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus
NCT06731218Diabetes Mellitus, Type 1, Diabetes Mellitus
DrugRGB-5088
Hangzhou Reprogenix Bioscience, Inc
Phase 1
10
Tianjin
2025-02-17
Recruiting
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
NCT06481735Acute Lymphocytic Leukemia
DrugsFludarabine·Cyclophosphamide
Chinese PLA General Hospital
Phase 1/2
30
Beijing, Changzhi, Tianjin
2025-02-15
Recruiting
The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation
NCT06792682Poor Graft Function
DrugEscalation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
15
Tianjin
2025-02-14
Active, closed
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
NCT06778967Type 2 Diabetes Mellitus (T2DM)
DrugsGZR18·Semaglutide
Gan & Lee Pharmaceuticals.
Phase 3
1,100
Tianjin
2025-02-13
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
NCT06941129Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-02-11
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
DrugAtogepant
AbbVie
Phase 3
468
Beijing, Guangzhou, Shijiazhuang, Wuhan, Suzhou, Xi'an, Taiyuan, Tianjin
2025-02-10
Not yet open
Clinical Classification of MAFLD Based Liver Biopsy
NCT06795646Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)
Beijing Friendship Hospital
Observational
2,000
Beijing, Hangzhou, Shanghai, Tianjin
2025-02-08
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Guangzhou, Xi'an, Changchun, Hanzhou, Shanghai, Tianjin, Zhengzhou
2025-02-07
Recruiting
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
NCT06793449Multiple Myeloma
DrugsASCT·Anti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2025-02-05
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
DrugsBGB-43395·Fulvestrant
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
By invitation
Laparoscopic Staging for Stage III Gastric Cancer
NCT07533825Gastric Cancer (GC), Gastric Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Not applicable
968
Tianjin
2025-02-01
Recruiting
Dose-attenuated IST and Hetrombopag in Elderly (โ‰ฅ65 Years) Patients With Severe Aplastic Anemia
NCT07010237Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
65
Tianjin
2025-02-01
Not yet open
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
68
Fuzhou, Guangzhou, Zhengzhou, Nanchang, Tianjin, Kunming
2025-02
Not yet open
Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
NCT06669169Heart Failure
Tasly Pharmaceutical Group Co., Ltd
Phase 2
288
Tianjin
2025-01-31
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsEquivalent)·Surovatamig·Acalabrutinib·Vincristine
AstraZeneca
Phase 1/2
408
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
2025-01-30
Recruiting
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
NCT06757855CML,Blast Phase
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
29
Tianjin
2025-01-26
Active, closed
A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
NCT06764303Paroxysmal Nocturnal Hemoglobinuria
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 2
24
Tianjin, Hangzhou
2025-01-23
Active, closed
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
NCT06744556AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
41
Tianjin
2025-01-21
Recruiting
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
NCT06783790AML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-01-20
Recruiting
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
NCT06776510Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-01-15
Recruiting
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
NCT06757504Autism Spectrum Disorder (ASD)
Shanghai Auzone Biological Technology Co., Ltd.
Phase 2
150
Beijing, Changsha, Chengdu, Nanjing, Tianjin
2025-01-13
Recruiting
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
NCT06744504AML, RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
284
Tianjin
2025-01-10
Active, closed
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
NCT06738485Congenital Hemophilia A
CSL Behring
Phase 3
60
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Tangshan, Tianjin
2025-01-09
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
NCT06772415Advanced Solid Tumor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
By invitation
Clinical Study on Deep Cervical Lymphatic Trunk Decompression Combined With Mid-Cervical Deep Lymph Node-External Jugular Vein Anastomosis for Alzheimer's Disease Treatment
NCT06936514Alzheimer's Disease
Oriental Neurosurgery Evidence-Based-Study Team
Not applicable
45
Tianjin
2025-01-08
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
NCT06801470Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
Phase 1
137
Tianjin
2025-01-08
Recruiting
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
NCT07017725Chronic Immune Thrombocytopenia
CASI pharmaceuticals, Inc.
Phase 1/2
75
Tangshan, Zhengzhou, Nanchang, Jinan, Tianjin, Kunming
2025-01-03
Recruiting
Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder
NCT06692361Major Depressive Disorder (MDD), Depression - Major Depressive Disorder
DrugsFMT·Escitalopram
Gang Wang
Not applicable
214
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jining, Chengdu, Tianjin, Dali
2025-01-01
Recruiting
TTE Improves Clinical Management of Stable Chest Pain
NCT07063147Transthorcic Echocardiography, Stable Angina Pectoris, Coronary Artery Disease, Major Adverse Cardiac Events
Tianjin Chest Hospital
Observational
50,000
Tianjin
2025-01-01
Recruiting
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
NCT06812039Hepato Cellular Carcinoma (HCC)
Fudan University
Phase 2
165
Fuzhou, Shanghai, Tianjin
2025-01-01
Recruiting
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
NCT07034326Non-Small Cell Lung Cancer, Electroacupuncture, Immune Checkpoint Inhibitors
Kong Fanming
Phase 2/3
405
Tianjin
2025-01-01
Recruiting
TACS on High-inflammatory and Refractory Depression
NCT06812923Treatment Resistant Depression (TRD), Inflammation
Tianjin Anding Hospital
Not applicable
52
Tianjin
2025-01-01
Active, closed
An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory Uveitis
NCT07773623Uveitis
DrugUpadacitinib
Tianjin Medical University
Phase 4
30
Tianjin
2025-01-01
Recruiting
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
NCT06766643Primary Liver Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
130
Tianjin
2025-01
Not yet open
A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors.
NCT06717009Kidney Neoplasms / Surgery, Robotic Surgical Procedures, Imaging, Three-Dimensional / Methods, Nephrectomy / Methods
Tianjin Medical University Cancer Institute and Hospital
Not applicable
350
Tianjin
2025-01
Recruiting
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
NCT06745687High Risk Smoldering Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2024-12-30
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 3
62
Beijing, Guangzhou, Haerbin, Zhengzhou, Shanghai, Chengdu, Tianjin, Wenzhou
2024-12-27
By invitation
Early Prediction of Gestational Diabetes in High-risk Women Based on Breath Metabolomics
NCT06753734Gestational Diabetes
Tianjin Central Hospital of Gynecology Obstetrics
Observational
600
Tianjin
2024-12-25
Recruiting
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06716658Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia, Cutaneous T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
48
Tianjin
2024-12-25
Recruiting
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
NCT06760364Advanced Pancreatic Cancers
Tianjin Medical University Cancer Institute and Hospital
Phase 1
21
Tianjin
2024-12-25
Recruiting
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
NCT06704555Follicular Lymphoma
DrugsVincristine·Doxorubicin·Prednisone·Rituximab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-12-20
Recruiting
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
20
Hefei, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Beijing, Tianjin
2024-12-16
Recruiting
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
NCT07028970Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Recruiting
Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder
NCT07031544Obsessive - Compulsive Disorder
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Recruiting
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
NCT06621563Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
DrugsHS-20117·Capeox·MFOLFOX6·Folfiri
Hansoh BioMedical R&D Company
Phase 1
780
Tianjin
2024-12-14
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME
NCT06708260Diabetic Macular Edema (DME)
EnnovaBio
Phase 2
60
Tianjin
2024-12-12
Rows per page Showing 401–500 of 940
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.